Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Research hypothesis:
Research issues:
The basic pathophysiological mechanism of gestational diabetes is insulin resistance formed as a result of the production of placental hormones. It turned out as atherosclerosis, chronic cardiovascular diseases and diabetes share common pathophysiological mechanisms, which is nonphysiological activation of the endothelium. CRP is an acute phase protein that is synthesized in the liver to stimulate IL-6. It is a sensitive marker of inflammation and good predictor of the development of preeclampsia while the research results CRP as a predictor of gestational diabetes inconsistent. Homocysteine is a marker of endothelial dysfunction and oxidative stress. Elevated homocysteine levels are a factor risk of cardiovascular disease, and in pregnancy is associated with preeclampsia, spontaneous abortions and placental abruption.Proper adjustment of uteroplacental blood vessels is necessary for the orderly course of pregnancy these deviations from normal endothelial function will lead to pregnancy disorders.
This study is an extrapolation of recognized markers of cardiovascular risk to gestational diabetes for the purpose of predicting an adverse perinatal outcome. Examined the association of the combination of the hs-CRP marker and homocysteine with gestational diabetes and pregnancy outcome and the correlation of homocysteine and folic acid concentration acid and vitamin B12.
Research hypothesis:
Research goals:
Respondents:
Criteria for inclusion in the research:
Exclusion criteria:
This enzyme is important for the metabolism of folate, B12, homocysteine.The diagnosis of gestational diabetes will be based on the results of the HAPO study, which is also accepted by the WHO. All respondents will be measured values of hs-CRP, homocysteine, folic acid and vitamin B12 in serum, at gestational age between 24-28 weeks of gestation and compare between test and control groups. The correlation of folate acid and vitamin B12 it will be examined the conection between homocysteine values in serum.
Using patients' medical histories we will monitore examined parameters: birth weight and length of the newborn, Apgar sum newborns in the 1st and 5th minutes, the development of hypertensive pregnancy disorders (hypertension, preeclampsia), HbA1c, BMI values and weight gain in pregnancy, gestational age, frequency of induced labor, cesarean section and surgically completed vaginal delivery, frequency of shoulder dystocia, presence meconium fruits, polyhydramnios, oligohydramnios and hypothyroidism. Statistical analysis of the data will assess the association of pregnancy outcomes with hs-CRP and homocysteine values in both study groups of pregnant women.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pregnant women with GDM | Pregnant women with GDM |
| |
| Pregnant women without GDM | Pregnant women without GDM |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and HS CRP | Other | Periferal Blood sampling and determination of MTHFR mutation,vitamin B12, folic acid, homocystein and high sensitive CRP |
| Measure | Description | Time Frame |
|---|---|---|
| Whether increased hs crp and homocysteine values are associated with poorer perinatal outcome | We will meassure hs CRP and homocysteine levels in pregnant women with GDM and compare to hs CRP and homocysteine levels in pregnant women with normal glucose metabolism | Between 24 and 28 weeks of gestation |
| carriers of the MTHFR gene mutation have higher serum homocysteine concentrations in the blood | We will compare serum homocysteine levels in pregnant carriers of the MTHFR gene mutation and pregnant women normal MTHFR gene mutation. | Between 24 and 28 weeks of gestation |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Pregnant women
Population of women who were hospitalized at the gynecology and obstretics clinic in Mostar.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Vajdana Tomic, prof. dr | Faculty of Health Studies, Mostar | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Faculty of health studies, Mostar | Mostar | 88000 | Bosnia and Herzegovina | |||
| University of Mostar |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37622180 | Derived | Boskovic A, Cuk A, Mandrapa V, Dugandzic Simic A, Cvetkovic I, Orlovic Vlaho M, Kresic T, Tomic T, Tomic V. Association of MTHFR polymorphism, folic acid and vitamin B12 with serum homocysteine levels in pregnant women. Biomol Biomed. 2024 Jan 3;24(1):138-143. doi: 10.17305/bb.2023.9260. |
| Label | URL |
|---|---|
| Chemical pathology of homocysteine. IV. Excitotoxicity, oxidative stress, endothelial dysfunction, and inflammation | View source |
Not provided
All of the individual participant data collected during the trial, after deidentification.
Beginnibg 3 months and ending 5 Years folowing article publication.
Investigators whose proposed use the Data has been approved by an Independent review committee identified for this purpose.
Not provided
Not provided
Not provided
Not provided
Not provided
Periferal blood.
| Mostar |
| 88000 |
| Bosnia and Herzegovina |
| First-Trimester Screening for Gestational Diabetes Mellitus Based on Maternal Characteristics and History | View source |
| Endothelial dysfunction - a major mediator of diabetic vascular disease | View source |
| Inflammatory and Other Biomarkers: Role in Pathophysiology and Prediction of Gestational Diabetes Mellitus | View source |
| ID | Term |
|---|---|
| D016640 | Diabetes, Gestational |
| ID | Term |
|---|---|
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001800 | Blood Specimen Collection |
| D014805 | Vitamin B 12 |
| D005492 | Folic Acid |
| D002097 | C-Reactive Protein |
| ID | Term |
|---|---|
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |
| D045728 | Corrinoids |
| D045725 | Tetrapyrroles |
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D047028 | Macrocyclic Compounds |
| D011083 | Polycyclic Compounds |
| D011622 | Pterins |
| D011621 | Pteridines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000418 | Albumins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D000209 | Acute-Phase Proteins |
| D001798 | Blood Proteins |
| D007162 | Immunoproteins |
Not provided
Not provided